Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey

Trial Profile

Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 15 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top